Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
20/20 Biolabs Inc. (AIDX)
Gaithersburg, MD, US
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Based on only 1 article — low confidence
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.08% | -18.40% | -37.80% | -75.00% | -95.72% | -95.72% | -95.72% | -95.72% | -95.72% | -95.72% | -95.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | +1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
5.00
+799.3%
|
| Last Quarter | 1 |
5.00
+799.3%
|
| Last Year | 1 |
5.00
+799.3%
|
| All Time | 1 |
5.00
+799.3%
|
-
Revenue growth Medical - Care Facilities: +10.2%+116,608.5% ★ Q1'26: +5.2% (vs Q2'23)
-
EPS growth Medical - Care Facilities: +19.2%+100.0% ★ Q1'26: +22.2% (vs Q2'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-155.2% Q1'26: -364.8% (vs Q2'23)
-
EBIT margin Medical - Care Facilities: +11.3%+0.0% Q1'26: +0.0% (vs Q2'23)
-
ROIC Medical - Care Facilities: +6.8%+0.0% Q1'26: +0.0% (vs Q2'23)
-
Share dilution Medical - Care Facilities: +0.0%-100.0% ★ Q1'26: +60.6% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×-0.39× Q1'26: -0.11× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CRESSET ASSET MANAGEMENT, LLC | 264.4K +264.4K (+100.0%) | 497.0K +497.0K (+100.0%) | 5.44% +5.444 pp | 0.00% +0.002 pp | USD1.88 +0.0% | 1 qtrs NEW |
| 2 | CITADEL ADVISORS LLC | 16.2K +16.2K (+100.0%) | 30.5K +30.5K (+100.0%) | 0.33% +0.334 pp | 0.00% +0.000 pp | USD1.88 +0.0% | 1 qtrs NEW |
| 3 | XTX TOPCO LTD | 10.3K +10.3K (+100.0%) | 19.4K +19.4K (+100.0%) | 0.21% +0.213 pp | 0.00% +0.000 pp | USD1.88 +0.0% | 1 qtrs NEW |
| 4 | UBS GROUP AG | 8.3K +8.3K (+100.0%) | 15.6K +15.6K (+100.0%) | 0.17% +0.171 pp | 0.00% +0.000 pp | USD1.88 +0.0% | 1 qtrs NEW |
| 5 | MAI CAPITAL MANAGEMENT | 1.0K +1.0K (+100.0%) | 1.9K +1.9K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD1.88 +0.0% | 1 qtrs NEW |
| 6 | TOTH FINANCIAL ADVISORY CORP | 157.00 +157.0 (+100.0%) | 296.00 +296.0 (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD1.88 +0.0% | 1 qtrs NEW |
| 7 | ALLWORTH FINANCIAL LP | 30.00 +30.0 (+100.0%) | 57.00 +57.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.87 +0.5% | 1 qtrs NEW |
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Zhou Jiming | Officer | A-Award | A | Stock Option | 150,000 | 1.88 | 282.0K | 150,000 | D | ↗ |
| 2026-04-02 | Bergman Alan B. | Officer | A-Award | A | Stock Option | 100,000 | 1.88 | 188.0K | 100,000 | D | ↗ |
| 2026-03-03 | Cohen Jonathan M | Director / Officer / 10% Owner | A-Award | A | Stock Option | 352,936 | 3.39 | 1.20M | 352,936 | D | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan Cohen | Founder, CEO, President & Director | 325.5K | male |
| Jiming Zhou | Chief Operating Officer | 225.6K | — |
| Michael S. Lebowitz | Chief Scientific Officer | 89.6K | — |
| David Lees | Director of Sales | — | male |
| Alan Bergman | Chief Financial Officer | — | male |
| Marc Gordon | Controller | — | — |
| Ronald R. Baker | Chief Business Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AIDX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
